Clinical management of diabetic foot infection: Diagnostics, therapeutics and the future

Expert Review of Anti-Infective Therapy

Volumn 5, Issue 1, 2007, Pages 117-127

  Matthews, Philippa C ^a   Berendt, Anthony R ^a   Lipsky, Benjamin A ^b  

^a OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Diabetes mellitus; Foot infection; Microbiology; Osteomyelitis; Pharmacology

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE; CEFALEXIN; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; ERTAPENEM; FUSIDIC ACID; GARENOXACIN; GATIFLOXACIN; GLYCOPEPTIDE; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; OFLOXACIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SULTAMICILLIN; TEICOPLANIN; TROVAFLOXACIN; UNINDEXED DRUG; VANCOMYCIN;

ANEMIA; ANTIBACTERIAL ACTIVITY; BLOOD ANALYSIS; BONE MARROW SUPPRESSION; CARDIOTOXICITY; CLINICAL TRIAL; COLITIS; COMPUTER ASSISTED TOMOGRAPHY; CULTURE TECHNIQUE; DEBRIDEMENT; DIABETIC FOOT; DIAGNOSTIC PROCEDURE; DIARRHEA; DRUG BIOAVAILABILITY; DRUG DOSE REGIMEN; DRUG POTENTIATION; DRUG TISSUE LEVEL; DRUG WITHDRAWAL; ECONOMIC ASPECT; EPIDEMIOLOGICAL DATA; ERADICATION THERAPY; HOSPITAL INFECTION; HUMAN; IMAGE ANALYSIS; LABORATORY TEST; LIVER TOXICITY; MAGGOT THERAPY; MENTAL STRESS; META ANALYSIS; MONOTHERAPY; MORBIDITY; NAUSEA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOMYELITIS; OXYGEN THERAPY; PATHOPHYSIOLOGY; REVIEW; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VASCULAR DISEASE; WOUND DRESSING; DIABETES MELLITUS; ECONOMICS; FORECASTING; MICROBIOLOGY; STAPHYLOCOCCUS INFECTION;

DIABETES COMPLICATIONS; DIABETES MELLITUS; DIABETIC FOOT; FORECASTING; HUMANS; STAPHYLOCOCCAL INFECTIONS;

EID: 33947727293     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.5.1.117     Document Type: Review

References (84)

1. Lavery LA, Armstrong DG, Wunderlich RP, Tredwell J, Boulton AJ. Diabetic foot syndrome: evaluating the prevalence and incidence of foot pathology in Mexican Americans and non-Hispanic whites from a diabetes disease management cohort. Diabetes Care 26(5), 1435-1438 (2003).
2. Lavery LA. Armstrong DG, Wunderlich RP, Mohler MJ, Wendel CS, Lipsky BA. Risk factors for foot infections in individuals with diabetes. Diabetes Care 29(6), 1288-1293 (2006).
3. Wild S, Roglic G, Green A. Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27(5), 1047-1053 (2004).
4. Boulton AJ, Vileikyte L, Ragnarson-Tennvall G, Apelqvist J. The global burden of diabetic foot disease. Lancet 366(9498), 1719-1724 (2005).
5. Price P. The diabetic foot: quality of life. Clin. Infect. Dis. 39(Suppl. 2), S129-S131 (2004).
6. Carmona GA, Hoffmeyer P, Herrmann FR et al. Major lower limb amputations in the elderly observed over ten years: the role of diabetes and peripheral arterial disease. Diabetes Metab. 31(5), 449-454 (2005).
7. Lipsky BA. Medical treatment of diabetic foot infections. Clin. Infect. Dis. 39(Suppl. 2), S104-S114 (2004).
8. Lipsky BA, Berendt AR, Deery HG et al. Diagnosis and treatment of diabetic foot infections. Clin. Infect. Dis. 39(7), 885-910 (2004).
9. Falanga V. Wound healing and its impairment in the diabetic foot. Lancet 366(9498), 1736-1743 (2005).
10. Zykova SN, Jenssen TG, Berdal M, Olsen R, Myklebust R, Seljelid R. Altered cytokine and nitric oxide secretion in vitro by macrophages from diabetic Type II-like db/db mice. Diabetes 49(9), 1451-1458 (2000).
11. Rich J, Lee JC. The pathogenesis of Staphylococcus aureus infection in the diabetic NOD mouse. Diabetes 54(10), 2904-2910 (2005).
12. Tentolouris N, Petrikkos G, Vallianou N et al. Prevalence of methicillin-resistant Staphylococcus aureus in infected and uninfected diabetic foot ulcers. Clin. Microbiol. Infect. 12(2), 186-189 (2006).
13. Kessler L, Piemont Y, Ortega F et al. Comparison of microbiological results of needle puncture vs superficial swab in infected diabetic foot ulcer with osteomyelitis. Diabet. Med 23(1), 99-102 (2006).
14. Abdulrazak A, Bitar ZI, Al-Shamali AA, Mobasher LA. Bacteriological study of diabetic foot infections. J. Diabetes Complications 19(3), 138-141 (2005).
15. Dang CN, Prasad YD, Boulton AJ, Jude EB. Methicillin-resistant Staphylococcus aureus in the diabetic foot clinic: a worsening problem. Diabet. Med. 20(2), 159-161 (2003).
16. Lew DP, Waldvogel FA. Osteomyelitis. N. Engl. J. Med. 336(14), 999-1007 (1997).
17. Jeffcoate WJ, Lipsky BA. Controversies in diagnosing and managing osteomyelitis of the foot in diabetes. Clin. Infect. Dis. 39(Suppl. 2), S115-S122 (2004).
18. Lipsky BA, Armstrong DG, Citron DM, Tice AD, Morgenstern DE, Abramson MA. Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial. Lancet 366(9498), 1695-1703 (2005).
19. Hartemann-Heurtier A, Robert J, Jacqueminet S et al. Diabetic foot ulcer and multidrug-resistant organisms: risk factors and impact. Diabet. Med. 21(7), 710-715 (2004).
20. King MD, Humphrey BJ, Wing YF, Kourbatova EV, Ray SM, Blumberg HM. Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections. Ann. Intern. Med. 144(5), 309-317 (2006).
21. Holtom PD, Zamorano D, Patzakis MJ. Osteomyelitis attributable to vancomycin-resistant enterococci. Clin. Orthop. Relat. Res. 2002(403), 38-44 (2002).
22. Appelbaum PC. MRSA - the tip of the iceberg. Clin. Microbiol. Infect. 12(Suppl. 2), 3-10 (2006).
23. Chang S, Sievert DM, Hageman JC et al. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N. Engl. J. Med. 348(14), 1342-1347 (2003).
24. Rodriguez-Bano J, Navarro MD, Romero L et al. Clinical and molecular epidemiology of extended-spectrum β-lactamase-producing Escherichia coli as a cause of nosocomial infection or colonization: implications for control. Clin. Infect. Dis. 42(1), 37-45 (2006).
25. Nelson EA, O'Meara S, Craig D et al. A series of systematic reviews to inform a decision analysis for sampling and treating infected diabetic foot ulcers. Health Technol. Assess. 10(12), 1-238 (2006).
26. Schinabeck MK, Johnson JL. Osteomyelitis in diabetic foot ulcers. Prompt diagnosis can avert amputation. Postgrad. Med. 118(1), 11-15 (2005).
27. Tan PL, Teh J. MRI of the diabetic foot: differentiation of infection from neuropathic change. Br. J. Radiol. DOI: 0:30036666v1 (2006) (Epub ahead of print).
28. Berendt AR, Lipsky B. Is this bone infected or not? Differentiating neuro-osteoarthropathy from osteomyelitis in the diabetic foot. Curr. Diab. Rep. 4(6), 424-429 (2004).
29. Cavanagh PR, Lipsky BA, Bradbury AW, Botek G. Treatment for diabetic foot ulcers. Lancet 366(9498), 1725-1735 (2005).
30. Armstrong DG, Lavery LA, Sariaya M, Ashry H. Leukocytosis is a poor indicator of acute osteomyelitis of the foot in diabetes mellitus. J. Foot Ankle Surg. 35(4), 280-283 (1996).
31. Eneroth M, Larsson J, Apelqvist J. Deep foot infections in patients with diabetes and foot ulcer: an entity with different characteristics, treatments, and prognosis. J. Diabetes Complications 13(5-6), 254-263 (1999).
32. Redkar R, Kalns J, Butler W et al. Identification of bacteria from a non-healing diabetic foot wound by 16 S rDNA sequencing. Mol. Cell. Probes 14(3), 163-169 (2000).
33. Rajbhandari SM, Sutton M, Davies C, Tesfaye S, Ward JD. 'Sausage toe': a reliable sign of underlying osteomyelitis. Diabet. Med. 17(1), 74-77 (2000).
34. Grayson ML, Gibbons GW, Balogh K, Levin E, Karchmer AW. Probing to bone in infected pedal ulcers. A clinical sign of underlying osteomyelitis in diabetic patients. JAMA. 273(9), 721-723 (1995).
35. Senneville E, Melliez H, Beltrand E et al. Culture of percutaneous bone biopsy specimens for diagnosis of diabetic foot osteomyelitis: concordance with ulcer swab cultures. Clin. Infect. Dis. 42(1), 57-62 (2006).
36. Zuluaga AF, Galvis W, Saldarriaga JG, Agudelo M, Salazar BE, Vesga O. Etiologic diagnosis of chronic osteomyelitis: a prospective study. Arch. Intern. Med. 166(1), 95-100 (2006).
37. Williams DT, Hilton JR, Harding KG. Diagnosing foot infection in diabetes. Clin. Infect. Dis. 39(Suppl. 2), S83-S86 (2004).
38. Ledermann HP, Morrison WB. Differential diagnosis of pedal osteomyelitis and diabetic neuroarthropathy: MR Imaging. Semin Musculoskelet. Radiol. 9(3), 272-283 (2005).
39. Chatha DS, Cunningham PM, Schweitzer ME. MR imaging of the diabetic foot: diagnostic challenges. Radiol. Clin. North Am. 43(4), 747-759 (2005).
40. Lipsky BA, Berendt AR, Embil J, De Lalla F. Diagnosing and treating diabetic foot infections. Diabetes Metab. Res. Rev. 20(Suppl. 1), S56-S64 (2004).
41. Schaper NC. Diabetic foot ulcer classification system for research purposes: a progress report on criteria for including patients in research studies. Diabetes Metab. Res. Rev. 20(Suppl. 1), S90-S95 (2004).
42. Robson MC, Steed DL, Franz MG. Wound healing: biologic features and approaches to maximize healing trajectories. Curr. Probl. Surg. 38(2), 72-140 (2001).
43. Senneville E. Antimicrobial interventions for the management of diabetic foot infections. Expert Opin. Pharmacother. 6(2), 263-273 (2005).
44. Nelson EA, O'Meara S, Golder S, Dalton J, Craig D, Iglesias C. Systematic review of antimicrobial treatments for diabetic foot ulcers. Diabet. Med. 23(4), 348-359 (2006).
45. Harkless L, Boghossian J, Pollak R et al. An open-label, randomized study comparing efficacy and safety of intravenous piperacillin/tazobactam and ampicillin/sulbactam for infected diabetic foot ulcers. Surg. Infect. (Larchmt.) 6(1), 27-40 (2005).
46. Legat FJ, Krause R, Zenahlik P et al. Penetration of piperacillin and tazobactam into inflamed soft tissue of patients with diabetic foot infection. Antimicrob. Agents Chemother. 49(10), 4368-4371 (2005).
47. Keating GM, Perry CM. Ertapenem: a review of its use in the treatment of bacterial infections. Drugs 65(15), 2151-2178 (2005).
48. Lipsky BA, Pecoraro RE, Larson SA. Hanley ME, Ahroni JH. Outpatient management of uncomplicated lower-extremity infections in diabetic patients. Arch. Intern. Med. 150(4), 790-797 (1990).
49. Grim SA, Rapp RP, Martin CA, Evans ME. Trimethoprim-sulfamethoxazole as a viable treatment option for infections caused by methicillin-resistant Staphylococcus aureus. Pharmacotherapy 25(2), 253-264 (2005).
50. Edmiston CE, Krepel CJ, Seabrook GR et al. In vitro activities of moxifloxacin against 900 aerobic and anaerobic surgical isolates from patients with intra-abdominal and diabetic foot infections. Antimicrob. Agents Chemother. 48(3), 1012-1016 (2004).
51. Muller M, Brunner M, Hollenstein U et al. Penetration of ciprofloxacin into the interstitial space of inflamed foot lesions in non-insulin-dependent diabetes mellitus patients. Antimicrob. Agents Chemother. 43(8), 2056-2058 (1999).
52. Oberdorfer K, Swoboda S, Hamann A et al. Tissue and serum levofloxacin concentrations in diabetic foot infection patients. J. Antimicrob. Chemother. 54(4), 836-839 (2004).
53. Edmiston CE Jr, Krepel CJ, Kehl KS et al. Comparative in vitro antimicrobial activity of a novel quinolone, garenoxacin, against aerobic and anaerobic microbial isolates recovered from general, vascular, cardiothoracic and otolaryngologic surgical patients. J. Antimicrob. Chemother. 56(5), 872-878 (2005).
54. Senneville E, Yazdanpanah Y, Cazaubiel M et al. Rifampicin-ofloxacin oral regimen for the treatment of mild to moderate diabetic foot osteomyelitis. J. Antimicrob. chemother. 48(6), 927-930 (2001).
55. Peppard WJ, Weigelt JA. Role of linezolid in the treatment of complicated skin and soft tissue infections. Expert Rev. Anti Infect. Ther. 4(3), 357-366 (2006).
56. McKinnon PS, Sorensen SV, Liu LZ, Itani KM. Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections. Ann. Pharmacother. 40(6), 1017-1023 (2006).
57. Lipsky BA, Itani K, Norden C. Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin- sulbactam/amoxicillin-clavulanate. Clin. Infect. Dis. 38(1), 17-24 (2004).
58. Rybak MJ, Hershberger E, Moldovan T, Grucz RG. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and -resistant strains. Antimicrob. Agents Chemother. 44(4), 1062-1066 (2000).
59. Lipsky BA. Stoutenburgh U. Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections. J. Antimicrob. Chemother. 55(2), 240-245 (2005).
60. Aneziokoro CO, Cannon JP, Pachucki CT, Lentino JR. The effectiveness and safety of oral linezolid for the primary and secondary treatment of osteomyelitis. J. Chemother. 17(6), 643-650 (2005).
61. Rao N, Ziran BH, Hall RA, Santa ER. Successful treatment of chronic bone and joint infections with oral linezolid. Clin. Orthop. Relat. Res. 2004(427), 67-71 (2004).
62. Fritsche TR, Sader HS, Stilwell MG, Dowzicky MJ, Jones RN. Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000-2004). Diagn. Microbiol. Infect. Dis. 52(3), 195-201 (2005).
63. Livermore DM. Can β-lactams be re-engineered to beat MRSA? Clin. Microbiol. Infect. 12(Suppl. 2), 11-16 (2006).
64. Legat FJ, Maier A, Dittrich P et al. Penetration of fosfomycin into inflammatory lesions in patients with cellulitis or diabetic foot syndrome. Antimicrob. Agents Chemother. 47(1), 371-374 (2003).
65. Stengel D, Gorzer E, Schinder M et al. Second-line treatment of limb-threatening diabetic foot infections with intravenous fosfomycin. J. Chemother. 17(5), 527-535 (2005).
66. Armstrong DG, Lipsky BA. Advances in the treatment of diabetic foot infections. Diabetes Technol. Ther. 6(2), 167-177 (2004).
67. Roeder B, Van Gils CC, Maling S. Antibiotic beads in the treatment of diabetic pedal osteomyelitis. J. Foot Ankle Surg. 39(2), 124-130 (2000).
68. Bergin SM, Wraight P. Silver based wound dressings and topical agents for treating diabetic foot ulcers. Cochrane Database Syst. Rev. (1), CD005082 (2006).
69. Reddy KV, Yedery RD, Aranha C. Antimicrobial peptides: premises and promises. Int. J. Antimicrob. Agents 24(6), 536-547 (2004).
70. Ge Y, MacDonald D, Henry MM et al. In vitro susceptibility to pexiganan of bacteria isolated from infected diabetic foot ulcers. Diagn. Microbiol. Infect. Dis. 35(1), 45-53 (1999).
71. Apelqvist J, Ragnarson-Tennvall G. Cavity foot ulcers in diabetic patients: a comparative study of cadexomer iodine ointment and standard treatment. An economic analysis alongside a clinical trial. Acta Derm. Venereol. 76(3), 231-235 (1996).
72. Tan JS. Foot infections in diabetic patients. Curr. Infect. Dis. Rep. 6(5), 377-379 (2004).
73. Sumpio BE, Lee T, Blume PA. Vascular evaluation and arterial reconstruction of the diabetic foot. Clin. Podiatr. Med. Surg. 20(4), 689-708 (2003).
74. Aksoy DY, Gurlek A, Cetinkaya Y et al. Change in the amputation profile in diabetic foot in a tertiary reference center: efficacy of team working. Exp. Clin. Endocrinol. Diabetes 112(9), 526-530 (2004).
75. Armstrong DG, Salas P, Short B et al. Maggot therapy in 'lower-extremity hospice' wound care: fewer amputations and more antibiotic-free days. J. Am. Podiatr. Med. Assoc. 95(3), 254-257 (2005).
76. Sherman RA. Maggot therapy for treating diabetic foot ulcers unresponsive to conventional therapy. Diabetes Care 26(2), 446-451 (2003).
77. Cruciani M, Lipsky BA. Mengoli C, de Lalla F. Are granulocyte colony-stimulating factors beneficial in treating diabetic foot infections? A meta-analysis. Diabetes Care 28(2), 454-460 (2005).
78. Berendt AR. Counterpoint: hyperbaric oxygen for diabetic foot wounds is not effective. Clin. Infect. Dis. 43(2), 193-198 (2006).
79. Barnes RC. Point: hyperbaric oxygen is beneficial for diabetic foot.wounds. Clin. Infect. Dis. 43(2), 188-192 (2006).
80. Sweitzer SM, Fann SA, Borg TK, Baynes JW, Yost MJ. What is the future of diabetic wound care?. Diabetes Educ. 32(2), 197-210 (2006).
81. Saar WE, Lee TH, Berlet GC. The economic burden of diabetic foot and ankle disorders. Foot Ankle Int. 26(1), 27-31 (2005).
82. Ragnarson-Tennvall G, Apelqvist J. Health-economic consequences of diabetic foot lesions. Clin. Infect. Dis. 39(Suppl 2), S132-S139 (2004).
83. Tennvall GF, Apelqvist J, Eneroth M. Costs of deep foot infections in patients with diabetes mellitus. Pharmacoeconomics 18(3), 225-238 (2000).
84. Clarke P, Gray A, Legood R, Briggs A, Holman R. The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65). Diabet. Med. 20(6), 442-450 (2003).